Andrew Leslie Denver

PFM Cornerstone Australian investment company focused on achieving exceptional long-term returns through the successful development of technology based growth businesses. The firm has over 180 years of collective management experience in bringing technology innovations to market and identify attractive technology based investments and actively manage them from proof of concept to commercialisation. PFM Cornerstone Limited will generally target opportunities with large market opportunities and technical skills. The main criteria for assessing a potential investment for the Cornerstone include a global product or service that offers potential for substantial sales within ten years, a proprietary technology product or service, clear ownership of intellectual property, a business plan to which management is committed, potential for significant margins, high sales growth and thus capital appreciation in the 30% PA range or better, satisfactory valuation and investment terms. Throughout an investee companies life the Cornerstone board continually evaluates exit options. Many investee companies may exit prior to commercialisation as strategic players typically become interested in acquisitions once a product has been proven.

Manufactures diagnostic test systems

Manufactures and distributes fluid testing and medical devices

Develops molecular diagnostic detection technologies

Develops and commercializes needle-free vaccine delivery solutions

Part of Vaxxas Pty Ltd., Vaxxas, Inc. is a company based in Cambridge, MA. The CEO of the company is David L. Hoey.

Functions as a College/University

Qbiotics Pty Ltd. is an Australian life sciences company specializing in the discovery and development of novel cell signalling small molecules. The company is based in Yungaburra, Australia. The company uses phenotypic screening to discover new solutions for challenging medical conditions, with a clinical focus on treatments for cancer and chronic wounds. Its lead oncology drug, tigilanol tiglate, targets solid tumours and is in phase II human clinical development, while a veterinary formulation is marketed as Stelfonta® in the USA and Australia. Qbiotics also has a wound healing drug candidate, EBC 1013, targeting chronic and acute wounds and burns, currently in phase I clinical development for venous leg ulcers.

Develops novel cell-signaling small molecules derived from natural sources for medical use